Treatment with Copaxone Plus Minocycline Showed Substantial
Reduction of Disease Activity in Patients with Active
Relapsing-Remitting Multiple Sclerosis
KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data from arandomized, double-blind study showed that a combination ofCOPAXONE(R) (glatiramer acetate injection) along with the oralantibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesionsof the brain by 63 percent (p=0.08) in patients with activerelapsing-
remitting multiple sclerosis (RRMS), as measured bymagnetic resonance im...
Treatment with Copaxone Plus Minocycline Showed Substantial
Reduction of Disease Activity in Patients with Active
Relapsing-Remitting Multiple Sclerosis
Treatment with Copaxone Plus Minocycline Showed SubstantialReduction of Disease Activity in Patients with ActiveRelapsing-
Remitting Multiple Sclerosis Combination Treatment With Antibiotic Further Reduced BrainLesions and Was Well Tolerated KANSAS CITY, Mo, May 4, 2007 - New data from a randomized,double-blind study showed that a combination of Copaxone(glatiramer acetate in...
Copaxone Treatment over Two Years after Short Term Induction with
Mitoxantrone Provided Sustained Benefits to Active
Relapsing-Remitting Multiple Sclerosis Patients
KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data havedemonstrated that relapsing-
remitting multiple sclerosis (RRMS)patients treated with COPAXONE(R) (glatiramer acetate injection)following brief immunosuppression with mitoxantrone experienced a90 percent reduction in magnetic resonance imaging (MRI)-monitoreddisease activity compared to their baseline. These benefits wereachieved...
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple
Sclerosis Presented at the American Academy of Neurology
Rituxan Significantly Reduced Signs of Disease Activity as Measuredby MRI and Relapse -- Genentech, Inc.(NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced thatpositive data from a Phase II clinical study of Rituxan®(rituximab) in patients with relapsing-
remitting multiple sclerosis(RRMS) were presented...
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple
Sclerosis Presented at the American Academy of Neurology
BOSTON--(BUSINESS WIRE)--May 1, 2007 - Genentech, Inc. (NYSE:DNA)and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive datafrom a Phase II clinical study of Rituxan(R) (rituximab) inpatients with relapsing-
remitting multiple sclerosis (RRMS) werepresented today at the American Academy of Neurology annual meetingheld in Boston. Rituxan is a therapeutic antibody that targets andselectiv...
More>>